Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst

4. Eli Lilly And Co (NYSE:LLY)

Number of Hedge Funds Investors: 119

Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, immunology and neuroscience, Redditors believe the company can offset any potential weakness in GLP-1 drugs amid the US government’s push to lower prices.

The company recently achieved the $1 trillion market cap milestone. The stock is up 36% so far this year. LLY bulls believe it has more upside potential amid strong growth from weight-loss drugs and other treatments, including diabetes, Alzheimer’s, and cancer.

While the stock’s P/E ratio remains elevated, some analysts believe it deserves a premium due to strong revenue growth. Over the past 12 months, LLY saw about 45% revenue growth, higher than its peers.

Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its third quarter 2025 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity. Shares declined after Phase 3 data for Lilly’s oral orforglipron in obesity fell short of elevated investor expectations. Investors had anticipated roughly 13% to 14% placebo-adjusted weight loss, while the trial showed 11.5%. The stock was also pressured by broader regulatory uncertainty related to potential sector tariffs and drug pricing risks. We view these risks as manageable and believe Lilly is among the least exposed pharmaceutical companies to both. We continue to believe orforglipron will be an important treatment option, as physicians and patients are likely to value the convenience of a daily oral therapy. Long term, we expect the GLP-1 drug class to become the standard of care for diabetes and obesity, ultimately representing a $150 billion-plus market, and believe Lilly possesses the leading portfolio in this category. In our view, GLP-1 adoption remains in the early stages, and continued uptake should drive a near doubling of Lilly’s total revenues by 2030.”